FOLD sure fits the buy low sell high formula....especially with the PPS paid by Glaxo...and the bottom looks like it might be in as well.
have you seen any projections on the potential revenue stream for FOLD if AMIGAL receives FDA approval? Or is this all about the pipeline and strong AMIGAL data verifies everything to follow?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.